Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Omega-3 carboxylic acid · 1 trial · 2 indications
To evaluate the efficacy of Epanova compared to placebo with respect to reduction in liver fat content (%) at the end of 12 weeks of double-blinded treatment.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| Omega-3 carboxylic acids 4g / day | EXPERIMENTAL | - |
| Fenofibrate 200mg | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo matching to Omega-3 carboxylic acids (olive oil) |
| Omega-3 carboxylic acid | DRUG | 4 g administered as 4 x 1 g capsules |
| Fenofibrate 200mg | DRUG | 200mg capsule administered once daily |
Inclusion Criteria: - Provision of informed consent * Men or women ≥40 years and ≤75 years with suitable veins for cannulation or repeated venepuncture * Have serum triglycerides ≥1.7 mM * Have liver fat content as assessed by MRI \>5.5% * Have a body mass index (BMI) \>25 and ≤40 kg/m2 , Exclus...
Omega-3 carboxylic acid is an investigational small molecule developed by AstraZeneca PLC (ticker AZN) for metabolic disease. It has been studied in non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia. Development has reached Phase 2.
Omega-3 carboxylic acid has been studied for non-alcoholic fatty liver disease (NAFLD) in overweight adults, with a secondary focus on hypertriglyceridemia. The Phase 2 trial evaluated its effect on liver fat. It is investigational and not approved for this use.
Omega-3 carboxylic acid is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the Phase 2 trial of the drug in NAFLD and hypertriglyceridemia.
Omega-3 carboxylic acid is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are ongoing. The drug is investigational and has not been approved for any indication.
Omega-3 carboxylic acid has been evaluated in one completed Phase 2 trial, NCT02354976. This double-blind, randomized, placebo-controlled study compared Epanova and fenofibrate on liver fat in overweight subjects with NAFLD and hypertriglyceridemia. It enrolled 78 participants in Sweden.
Yes, Omega-3 carboxylic acid is also known as Epanova. The Phase 2 trial NCT02354976 was titled as a comparison of Epanova and fenofibrate on liver fat in overweight subjects, confirming the alternative name.